Kura Oncology (NASDAQ:KURA) Coverage Initiated by Analysts at Deutsche Bank
Deutsche Bank started coverage on shares of Kura Oncology (NASDAQ:KURA) in a report published on Thursday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $28.00 price target on the stock.
Other equities research analysts have also recently issued reports about the stock. HC Wainwright set a $31.00 price objective on shares of Kura Oncology and gave the company a buy rating in a research report on Wednesday, May 8th. Leerink Swann set a $27.00 price objective on shares of Kura Oncology and gave the company a buy rating in a research report on Saturday, June 15th. Citigroup set a $27.00 price objective on shares of PhaseBio Pharmaceuticals and gave the company a buy rating in a research report on Friday, May 24th. Cowen reaffirmed a buy rating on shares of Kura Oncology in a research report on Monday, June 17th. Finally, Wedbush began coverage on shares of Pinterest in a research report on Monday, June 17th. They issued an outperform rating and a $33.00 price objective on the stock. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $28.00.
Shares of NASDAQ KURA opened at $19.05 on Thursday. The stock’s fifty day moving average price is $18.89. Kura Oncology has a twelve month low of $10.20 and a twelve month high of $22.00. The company has a current ratio of 13.80, a quick ratio of 13.80 and a debt-to-equity ratio of 0.05.
In other Kura Oncology news, insider Antonio Gualberto sold 18,000 shares of Kura Oncology stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $21.11, for a total value of $379,980.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.30% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the business. Great West Life Assurance Co. Can acquired a new stake in Kura Oncology in the 4th quarter valued at $62,000. BlackRock Inc. increased its stake in Kura Oncology by 0.6% in the 4th quarter. BlackRock Inc. now owns 2,409,979 shares of the company’s stock valued at $33,836,000 after buying an additional 13,842 shares during the last quarter. Fosun International Ltd increased its stake in Kura Oncology by 49.8% in the 1st quarter. Fosun International Ltd now owns 305,958 shares of the company’s stock valued at $4,972,000 after buying an additional 101,724 shares during the last quarter. Geode Capital Management LLC increased its stake in Kura Oncology by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 354,010 shares of the company’s stock valued at $4,970,000 after buying an additional 43,205 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Kura Oncology by 8.2% in the 4th quarter. Bank of New York Mellon Corp now owns 121,473 shares of the company’s stock valued at $1,706,000 after buying an additional 9,218 shares during the last quarter. Hedge funds and other institutional investors own 83.89% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Read More: What is the definition of a trade war?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.